The MD&A and Financials for the 3 months ending July 31 are up on SEDAR (been there since Sept 30th actually).

One new item I saw was that they expect to start the Phase 2 portion of the Pfizer TNBC trial at the end of calendar 2019 or early calendar 2020. So they must be nearing the end of the Phase 1b safety, pharmacokinetic, pharmacodynamic and Phase 2 dose finding portion. 

Also, regarding the Newsoara license agreement there are upcoming milestones: 

"The near-term development milestone payments includes $5.0 million for completion of Zenith’s current Phase 2 clinical study with ZEN-3694 in metastatic castration-resistant prostate cancer (subject to Newsoara’s satisfaction with the study’s results and election to continue development); and $6.5 million for completion of either a Phase 3 clinical trial or a clinical study which results in Zenith receiving accelerated approval by the US Food and Drug Administration (“FDA”) (subject to Newsoara’s satisfaction with the study’s results). In addition, Zenith is eligible to receive tiered royalty payments on sales of products once commercialization commences and Newsoara achieves sales. No amounts have been recognized for these milestone or royalty payments at July 31, 2019."